91插插视频,91熟女露脸视频,精品国产综合一区,跪舔内射人妻

CN
Latest stock price:
XLifes once again named “top 50 biotechnology enterprises” of GAB
Time:2019-10-17  

Source: Guangdong Medical Valley

On October 16, the second award ceremony for the top 50 biotechnology innovation enterprises in Guangdong-Hong Kong-Macao Greater Bay Area "(GBA")was held in Guangzhou. Xiangxue Life Sciences, Ltd (herein after referred to as XLifes"), a subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd., has won the award for the second consecutive year. 

The purpose of the award is to promote integration of production, learning and research, discover biotechnology unicorns, and identify leaders of the biotechnology industry in the GBA. The top 50 enterprises include enterprises in medical devices, biopharmaceuticals (including biotherapy, cell therapy, gene therapy) and medical services (including mobile medicine, pension service, physical examination center, etc.).

The panel for the award composed of experts from government agencies, research institutions, investment institutions, medical institutions, etc. After comprehensive evaluation of the technological innovation and future development prospect of the runner up enterprises through field visits and face-to-face discussions with the enterprises. 

 
【About Xiangxue Life Sciences, Ltd】

Xiangxue Life Sciences, Ltd (“XLifes“) is a biomedical company focusing on TCR-based therapies for cancer. Our main technological platform is TCR Affinity Enhanced Specific T-cells (TAEST).

The product is a kind of affinity optimized TCR engineered T cells (3rd generation TCR-T). With its enhanced TCR affinity, TAEST targets specifically the intracellular and extracellular tumor antigens and exhibits encouraging clinical efficacy and safety profile. In addition, it has longer in vivo persistency and good therapeutic effects in solid tumors.

We have obtained the investigational new drug (IND) approval for our product TAEST16001 from the NMPA in March 2019, and now we are in the progress of recruiting patients. This is the first TCR-T cell therapy IND approved by the NMPA in China.
XPH Group
XLifeSc
Pharmaceutical
TCM Resources
亚洲精品视频666| 成人电影1区2区| 一区二区三区亚洲夫妻性生活| 户外日逼免费大全视频| 三级片视频操逼| 周国产精品久久| www.99人妻爽| 欧美激情黄色性视频| 久久av在线一区| 女同久久依依一区| 超碰在线熟练| 小女福利视频网| 不卡一区AV不卡| 午夜孕妇黄色电影| 日本一区二区三区的视频| 黄色网页免费| 欧美第一淫网| 国产a欧美| 少妇99精品| 贾乃亮和李小璐合唱的歌曲| 亚洲片久久| 欧美亚洲视频图片区| 久久久久久久久就就久久久久久久久| 国产精品一区超碰| 大香蕉国产电影av| 欧美久久美女免费| 欧美视频小说在线播放| 小穴被填满视频免费| 国产欧美综合在线看| 欧美日韩国产在线第一| 产久久久久久久www| 精品国产乱码1区2区3区无码| 美女按摩处女操逼三级片| 女人吃鸡巴在线看| 人人干人人爽天天操| 成人年天堂| 嫩粉AV在线| 欧美性爱视频日韩| 在线日韩 图区一区| 日韩一区操擦| 九九偷拍夫妻性生活|